Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in Generalized Myasthenia Gravis
NCT06744920Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of remibrutinib in myasthenia gravis (MG), sponsored by Novartis. Started Feb 2025; status: active, not recruiting.
02
Drugs
remibrutinib
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06744920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06744920.